guanylate cyclase-c

Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

Linaclotide, developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, is a potent and selective guanylate cyclase C agonist.

Linaclotide acetate is used as an oral guanylate cyclase C agonist linaclotide; 14 amino acid peptide for the potential treatment of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation.

Plecanatide acetate is a agonist of guanylate cyclase-C (GC-C) receptor( EC50 of 190 nM in T84 cells), and shows anti-inflammatory activity in models of murine colitis.

MM 419447 is a guanylate cyclase-C agonist, and it is a metabolite of linaclotide. This compound, MM 419447, shows promise in the field of irritable bowel syndrome with constipation (IBS-C) research.

Dolcanatide, an orally active guanylate cyclase-C (GC-C) agonist, exhibits laxative, anti-nociceptive, and anti-inflammatory properties. It is utilized in research concerning inflammatory bowel disease [1] [2].

Indusatumab vedotin is an antibody-drug conjugate (ADC) consisting of an antibody targeting human guanylate cyclase C (GCC) conjugated with the microtubule inhibitor monomethyl auristatin. It can inhibit the proliferation of pancreatic cancer cells, arrest the cell cycle at G2/M phase, and induce apoptosis.

C-Type Natriuretic Peptide (1-53), from porcine, rat, and mouse sources, serves as an activator of particulate guanylate cyclase B (pGC-B), prominently found in endothelial cells, kidneys, and the heart. This peptide efficiently mediates a potent anti-fibrotic effect in human cardiac and renal fibroblasts through the production of the second messenger cGMP.

Uroguanylin (human) (TFA) is the natural ligand for the guanylate cyclase C (GCC) receptor expressed in metastatic colorectal cancer tumors. In animal models of human colon cancer, Uroguanylin (human) (TFA) demonstrates antitumor activity.